Press coverage about Second Sight Medical Products (NASDAQ:EYES) has been trending positive on Sunday, Accern Sentiment reports. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Second Sight Medical Products earned a news impact score of 0.35 on Accern’s scale. Accern also gave news stories about the medical device company an impact score of 44.3592057499593 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Several brokerages have recently issued reports on EYES. HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of Second Sight Medical Products in a research note on Thursday, July 6th. Zacks Investment Research upgraded shares of Second Sight Medical Products from a “sell” rating to a “hold” rating in a research note on Wednesday, September 13th.

Shares of Second Sight Medical Products (NASDAQ:EYES) traded down 0.83% on Friday, hitting $1.20. 117,713 shares of the stock traded hands. The stock’s market cap is $68.15 million. The stock’s 50 day moving average price is $1.10 and its 200 day moving average price is $1.19. Second Sight Medical Products has a 52-week low of $0.90 and a 52-week high of $3.60.

Second Sight Medical Products (NASDAQ:EYES) last posted its earnings results on Tuesday, August 1st. The medical device company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.01. The business had revenue of $2.24 million for the quarter, compared to the consensus estimate of $1.43 million. Second Sight Medical Products had a negative net margin of 646.89% and a negative return on equity of 168.49%. The company’s revenue for the quarter was up 124.0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.17) EPS. On average, equities analysts expect that Second Sight Medical Products will post ($0.55) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Positive Media Coverage Somewhat Unlikely to Affect Second Sight Medical Products (EYES) Stock Price” was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.watchlistnews.com/positive-media-coverage-somewhat-unlikely-to-affect-second-sight-medical-products-eyes-stock-price/1601685.html.

About Second Sight Medical Products

Second Sight Medical Products, Inc is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight.

Insider Buying and Selling by Quarter for Second Sight Medical Products (NASDAQ:EYES)

Receive News & Ratings for Second Sight Medical Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.